Ontology highlight
ABSTRACT:
SUBMITTER: Sehn LH
PROVIDER: S-EPMC5087315 | biostudies-literature | 2015 Oct
REPOSITORIES: biostudies-literature
Sehn Laurie H LH Goy Andre A Offner Fritz C FC Martinelli Giovanni G Caballero M Dolores MD Gadeberg Ole O Baetz Tara T Zelenetz Andrew D AD Gaidano Gianluca G Fayad Luis E LE Buckstein Rena R Friedberg Jonathan W JW Crump Michael M Jaksic Branimir B Zinzani Pier Luigi PL Padmanabhan Iyer Swaminathan S Sahin Deniz D Chai Akiko A Fingerle-Rowson Günter G Press Oliver W OW
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20150817 30
<h4>Purpose</h4>Obinutuzumab (GA101), a novel glycoengineered type II anti-CD20 monoclonal antibody, demonstrated responses in single-arm studies of patients with relapsed/refractory non-Hodgkin lymphoma. This is the first prospective, randomized study comparing safety and efficacy of obinutuzumab with rituximab in relapsed indolent lymphoma. The primary end point of this study was the overall response rate (ORR) in patients with follicular lymphoma after induction and safety in patients with in ...[more]